ENZ, EXK, URZ, SGS - CRWEFinance.com Stock Report! Jan 12th 2011

**************************************************************************

Endeavour Silver Corp. (AMEX:EXK) announced that the Company set a new record for quarterly silver production in Q4, 2010, up 15% to 895,931 oz silver compared to Q4, 2009. Gold output also jumped to a new high in Q4, 2010, up 6% to 4,871 oz gold compared to Q4, 2009. As a result, Endeavour delivered its sixth consecutive year of silver production growth, up 26% year-on-year to 3.3 million oz silver in 2010. In addition, gold output rose even more sharply, up 33% to 17,713 oz gold in 2010 compared to 2009. Using the recent silver: gold ratio of 50:1 (base metals not included as equivalents), Endeavour produced 4.2 million oz silver equivalents in 2010, up 24% compared to 2009.

Endeavour Silver Corp., together with its subsidiaries, engages in the evaluation, acquisition, exploration, development, and exploitation of mineral properties, primarily silver in Mexico. It produces silver and gold from its underground mines at the Guanacevi mines project located in the state of Durango; and the Guanajuato mines project located in the state of Guanajuato.

**************************************************************************

Enzo Biochem, Inc. (NYSE:ENZ) reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

Total revenues for the first quarter of fiscal 2011 increased to $25.7 million, from $25.2 million a year ago, or 2%, despite slightly lower revenues at Life Sciences resulting from a program to emphasize higher margined products, and advanced 3% sequentially. Enzo Clinical Labs benefited from an increase in market share and a new provider contract.

Gross profit margin improved 17% to $13.5 million, or 53% of revenues, compared to the fiscal 2010 fourth quarter’s $11.5 million and was a slight improvement year over year. R&D expenses were $1.8 million, 28% lower than both a year ago and in the July 2010 quarter, and SG&A declined $0.5 million to $11.0 million, as a percentage of revenues down 3% from a year ago and 1% from the prior quarter. Overall operating expenses, including R&D, SG&A, legal and provision for uncollectible accounts were $14.6 million, a decline of 4% from last year’s first quarter and 7% from the preceding July period. The operating loss decreased 42%, to ($1.1) million from the corresponding year-ago period, while the net loss of ($1.1) million was 38% lower year over year. EBITDA, adjusted for approximately $1.1 million in both periods for depreciation and amortization, was $23,000, compared to a year ago EBITDA loss of ($959,000), an improvement of $936,000.

About Enzo Clinical Labs:

Enzo Clinical Labs is much more than a highly respected clinical laboratory. Its lab is utilized extensively to demonstrate the benefits of gene-based products developed at Enzo Life Sciences. It also plays an important role in the development of and performance of tests used to support the on going trials of Enzo Therapeutics.

They are one of the leading regional labs in the country, as they combine the extensive testing capabilities of a large laboratory with the convenience and personalized service of a local one. Enzo was one of the area's first laboratories to be awarded the prestigious College of American Pathologist (CAP) accreditation. This award indicates that Enzo has passed an extremely rigorous series of inspections far more sophisticated than those mandated by licensing authorities.

About Enzo Life Sciences:

Enzo Life Sciences is a leading manufacturer of high quality reagents, kits and products supplied to scientific researchers in academia, clinical research and drug discovery. With direct sales operations in US, Switzerland, Germany, UK, France and Benelux, Enzo Life Sciences also supports its 8000 products through a global network of dedicated distributors.

Enzo Life Sciences rapidly growing catalogue of over 8000 products, technologies and services is sold to scientists worldwide to “Enable Discovery in Life Sciences”. The catalogue of products covers a wide area of science and used in research of DNA, Proteins and Cells. Our areas of focus include:

a) DNA, RNA and Protein Quantization Systems
b) Genomics and Molecular Biology
c) Labels and Probes
d) Research Assay Kits
e) Compound Libraries
f) Biochemicals, enzymes, proteins, and immunological in the fields.

About Enzo Biochem:

Enzo Biochem is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide.

More about ENZ at: www.enzo.com , www.enzolifesciences.com

**************************************************************************

Uranerz Energy Corp. (AMEX:URZ) announced that the State of Wyoming, Department of Environmental Quality ("WDEQ"), has issued the commercial Permit to Mine (Permit Number 778) for the Company's Nichols Ranch In-Situ Recovery ("ISR") Uranium Project located in Johnson and Campbell counties in the Central Powder River Basin of Wyoming, U.S.A. The Nichols Ranch project contains an estimated 5.5 million pounds of uranium resources and will serve as a platform to develop the Company's other Powder River Basin projects through the permit amendment provisions of the regulatory process.

Uranerz Energy Corporation, an exploration stage company, engages in the acquisition, exploitation, and development of uranium properties. The company principally focuses on the exploration of its properties in the Powder River Basin area of Wyoming encompassing approximately 119,312 acres, as well as owns interests in properties located in the Great Divide Basin area of Wyoming., Texas and in Saskatchewan, Canada.

**************************************************************************

Stream Global Services, Inc. (AMEX:SGS) announced that it has appointed Jim Radzicki as Executive Vice President and Chief Technology Officer. Based out of the company’s Wellesley, Mass., headquarters, Mr. Radzicki will be responsible for driving Stream’s overall information and technology strategy. An accomplished executive in the technology and BPO industry, Mr. Radzicki brings nearly 15 years of strategic technology and information systems experience to Stream. He comes to Stream from Network Solutions, the leading provider of online services for small businesses.

Stream Global Services, Inc. operates as a global business process outsourcing service provider. The company offers customer relationship management services, including sales, customer care, and technical support.

********************************************************************

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.